By market close, shares had taken off 7.8% to $2.37. Trading volume of 4.25 million was more than double its three-month daily average.
The molecular diagnostic equipment specialist recorded a net loss of $18.9 million, or 16 cents a share, for the three months to December, in line with expectations of analysts surveyed by Thomson Reuters.
Revenue of $45.1 million, though 34% higher than the year-ago quarter, fell short of consensus by $1.92 million.
The San Diego-based business said it hopes to achieve break-even quarterly earnings and positive cash flow by the fourth quarter of 2014.
Must Read: Ukraine Won't Become a Cold War Throwback